Sign in
Active, not recruitingNo phase

A Neurofeedback Booster for Emotion Regulation Therapy

Key facts

Who runs it
Christian Paret
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
44 people, planned
Started
21 Jul 2020
Ended
Dec 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Neurofeedback
Record updated
11 March 2025

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • DSM-5 BPD diagnosis
  • informed consent
  • EtOH and tox negative on the day of neurofeedback
  • BSL-23 score >=1.87 at DBT halftime

Who cannot take part

  • epilepsy
  • life-time diagnosis schizophrenia or bipolar disorder I
  • significant current or past neurological illness
  • pharmacotherapy with opiates
  • standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed)
  • pregnancy
  • BMI<16.5
  • usual safety criteria for magnetic resonance imaging

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback will be administered to N=22 patients with BPD while they receive residential Dialectical Behavior Therapy treatment. In addition, outcomes are assessed from a control group with same sample size who do not receive the treatment.

The 2 groups in the trial

  • TreatmentTreatment being tested

    Treatment: Neurofeedback

  • ControlNo study treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
BrainBoost - A Neurofeedback Booster for Emotion Regulation Therapy
Publications
Record updated
11 March 2025